Physicians tend to rely on diagnostic criteria, including BMI, that can influence patients’ access to care, referrals, and insurance coverage for indicated interventions.
AMA J Ethics. 2023; 25(7):E507-513. doi:
10.1001/amajethics.2023.507.
Diagnostic utility of weight and body mass index is widely overestimated, and their use as health and wellness measures can be sources of iatrogenic harm.
AMA J Ethics. 2023; 25(7):E540-544. doi:
10.1001/amajethics.2023.540.
Annika Brakebill, A. Mark Fendrick, MD, and Jeffrey T. Kullgren, MD, MS, MPH
These key steps are ones health sector stakeholders should take to help patients and clinicians use pricing information to inform health decision making.
AMA J Ethics. 2022; 24(11):E1034-1039. doi:
10.1001/amajethics.2022.1034.
Jing Li, PhD, Robert Tyler Braun, PhD, Sophia Kakarala, and Holly G. Prigerson, PhD
For dying patients and their loved ones to make informed decisions, physicians must share adequate information about prognoses, prospective benefits and harms of specific interventions, and costs.
AMA J Ethics. 2022; 24(11):E1040-1048. doi:
10.1001/amajethics.2022.1040.
More transparent pricing would allow patients and families to make better decisions, but there are limitations to how reliably it promotes efficiency and market discipline.
AMA J Ethics. 2022; 24(11):E1069-1074. doi:
10.1001/amajethics.2022.1069.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022; 24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.